IP Library Granted Patent US 10,053,447
Granted Patent B2
US 10,053,447 · App. 13/330,993 · Granted Aug 21, 2018

Fluorescent compounds

Inventors: Greg Hermanson (Loves Park, IL); Peter T. Czerney (Weimar, DE); Surbhi Desai (Rockford, IL); Matthias S. Wenzel (Jena, DE); Boguslawa Dworecki (Rockford, IL); Frank G. Lehmann (Jena, DE)
Assignees: Pierce Biotechnology, Inc; Dyomics GmbH
C07D403/06C07D209/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,053,447
App. No.
13/330,993
Granted
Aug 21, 2018
Kind
B2
Abstract

Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Claims (18)

1. A compound of general formula I

where

each of R 1 and R 2 is sulfoalkyl;

X is selected from the group consisting of —NHS (hydroxysuccinimidyl), —O-TFP (2,3,5,6-tetrafluorophenm), —NR-L-maleimide and combinations thereof where R is —H or an aliphatic or heteroaliphatic group, and L is selected from the group consisting of a divalent linear, crossed, and cyclic alkyl group optionally substituted by at least one oxygen atom and/or sulfur atom;

Kat is one or more cations necessary to balance the negative charge of the compound;

m is 0; o is 3; and n is 1.

2. A compound of general formula I

where

each of R1 and R2 is sulfoalkyl;

X is selected from the group consisting of —NHS (hydroxysuccinimidyl), —O-TFP (2,3,5,6-tetrafluorophenm), —NR-L-maleimide and combinations thereof where R is —H or an aliphatic or heteroaliphatic group, and L is selected from the group consisting of a divalent linear, crossed, and cyclic alkyl group optionally substituted by at least one oxygen atom and/or sulfur atom;

Kat is one or more cations necessary to balance the negative charge of the compound;

m is 0; o is 3; and n is 2.

3. A compound of general formula I

where

each of R1 and R2 is sulfoalkyl;

X is selected from the group consisting of —NHS (hydroxysuccinimidyl), —O-TFP (2,3,5,6-tetrafluorophenm), —NR-L-maleimide and combinations thereof where R is —H or an aliphatic or heteroaliphatic group, and L is selected from the group consisting of a divalent linear, crossed, and cyclic alkyl group optionally substituted by at least one oxygen atom and/or sulfur atom;

Kat is one or more cations necessary to balance the negative charge of the compound;

m is 0; o is 3; and n is 3.

Assignments (2)
MERGER Recorded Mar 11, 2026
From: PIERCE BIOTECHNOLOGY, INC.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 075052/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2012
From: HERMANSON, GREG; CZERNEY, PETER T.; DESAI, SURBHI; WENZEL, MATTHIAS S.; DWORECKI, BOGUSLAWA; LEHMANN, FRANK G.
To: PIERCE BIOTECHNOLOGY, INC.; DYOMICS GMBH
Reel/Frame 027484/0328 →
Continuity (7)
Provisional Application 61425446 · Dec 21, 2010
Provisional Application 61446319 · Feb 24, 2011
Provisional Application 61480840 · Apr 29, 2011
Provisional Application 61482933 · May 5, 2011
Related Publication 20120156140A1 · Jun 21, 2012
Related Publication 20120294807A9 · Nov 22, 2012
Related Publication 20130251637A9 · Sep 26, 2013